<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Transcept Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/transcept-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALXA) Company News for October 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644#comments</comments>
		<pubDate>Thu, 06 Oct 2011 15:16:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexandria Real Estate Equities Inc]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[ARE]]></category>
		<category><![CDATA[General Maritime Corporation]]></category>
		<category><![CDATA[GMR]]></category>
		<category><![CDATA[NRG]]></category>
		<category><![CDATA[NRG Energy Inc.]]></category>
		<category><![CDATA[Red Hat Inc.]]></category>
		<category><![CDATA[RHT]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84644</guid>
		<description><![CDATA[•    Drug developer Transcept Pharmaceuticals Inc.’s (NASDAQ:TSPT) shares increased 33.77% to close at $8.08 after the company&#8217;s experimental sleep treatment got approved from the regulators •    Share prices of General Maritime Corp. (NYSE:GMR) declined 7.35%  after the company reported its plans for a possible restructuring •    Shares of power company NRG Energy Inc. (NYSE:NRG) shed 1.81% to close at $19.57 after the company lowered down its earnings outlook for 2011 •    Software company Red Hat Inc. (NYSE:RHT) announced that it would acquire software developer Gluster Inc. in a deal worth $136 million •    Share prices of phone carrier Sprint-Nextel (NYSE:S) advanced 4.76% on news that the company will offer the iPhone 4S on its inaugural day on 14th October •    Analysts at Goldman Sachs upgraded shares of Kinder Morgan (NYSE:KMI) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAC) Company News for September 16, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/09/16/bac-company-news-for-september-16-2011-corporate-summary/83423</link>
		<comments>http://www.stockbloghub.com/2011/09/16/bac-company-news-for-september-16-2011-corporate-summary/83423#comments</comments>
		<pubDate>Fri, 16 Sep 2011 16:17:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[FNDT]]></category>
		<category><![CDATA[Fundtech Limited]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[NCT]]></category>
		<category><![CDATA[Netflix Inc.]]></category>
		<category><![CDATA[Newcastle Investment Corporation]]></category>
		<category><![CDATA[NFLX]]></category>
		<category><![CDATA[Pier 1 Imports Inc.]]></category>
		<category><![CDATA[PIR]]></category>
		<category><![CDATA[SUPERVALU Inc.]]></category>
		<category><![CDATA[SVU]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83423</guid>
		<description><![CDATA[•    Pier 1 Imports (NYSE:PIR) posted Q2 EPS of $0.14, in line with Zacks Consensus Estimates. Revenues for the quarter rose 9.6% to $339.6 million •    Swiss bank UBS AG&#8217;s (NYSE:UBS) share prices fell 10.02% after the banking giant revealed that rogue trading in London has resulted in a loss of $2 billion. The investment bank also expressed fears of lower profits for the third quarter because of the loss •    Analysts at Goldman Sachs (NYSE:GS) added shares of integrated-circuit designer company Aeroflex Holding Corp (NYSE:ARX) to their conviction &#8220;Buy&#8221; list •    Share prices of online movie rental company Netflix, Inc. (NASDAQ:NFLX) declined 18.91% after the company lowered its outlook for subscribers in the U.S. for the fiscal third quarter •    Israeli financial services firm Fundtech Ltd.&#8217;s (NASDAQ:FNDT) share prices ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/16/bac-company-news-for-september-16-2011-corporate-summary/83423/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BA) Company News for July 14, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/14/ba-company-news-for-july-14-2011-corporate-summary/79066</link>
		<comments>http://www.stockbloghub.com/2011/07/14/ba-company-news-for-july-14-2011-corporate-summary/79066#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:45:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aerospace-Defense - Major Diversified]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[Clean Energy Fuels Corporation]]></category>
		<category><![CDATA[CLNE]]></category>
		<category><![CDATA[Electronic Arts Inc.]]></category>
		<category><![CDATA[ERTS]]></category>
		<category><![CDATA[Glu Mobile Inc.]]></category>
		<category><![CDATA[GLUU]]></category>
		<category><![CDATA[Grupo Televisa SA]]></category>
		<category><![CDATA[InterMune Inc]]></category>
		<category><![CDATA[Investment Technology Group Inc]]></category>
		<category><![CDATA[ITG]]></category>
		<category><![CDATA[ITMN]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[Linkedin Corporation]]></category>
		<category><![CDATA[LNKD]]></category>
		<category><![CDATA[TIE]]></category>
		<category><![CDATA[Titanium Metals Corporation]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>
		<category><![CDATA[TV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79066</guid>
		<description><![CDATA[•    Analysts at JP Morgan (NYSE:JPM) highlighted the prospects of the internet sector in a bullish note. Reacting to the development, shares prices of LinkedIn Corp. (NYSE:LNKD) rose 8.41% to close at $107.87 •    Shares of Titanium Metals Corp. (NYSE:TIE) increased 7.02% after the company announced the extension of its titanium supply agreement with Boeing Co. (NYSE:BA). According to a regulatory filing, the company&#8217;s outstanding shares came down after it bought back some of its own stock •    Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) said the FDA will not allow the company to market its insomnia drug Intermezzo. Following this development, shares of the bio-pharma company dropped 42.49% to end the day’s trade at $4.94 •    Kinetic Concepts Inc. (NYSE:KCI) announced that a private-equity consortium consisting of Apax Partners and two major ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/ba-company-news-for-july-14-2011-corporate-summary/79066/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NBIX) Focus Turns To Biotech Next Week</title>
		<link>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740</link>
		<comments>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740#comments</comments>
		<pubDate>Tue, 11 Jan 2011 23:46:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[Cytomedix Inc]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[DATA]]></category>
		<category><![CDATA[DATATRAK International Inc]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[GTF]]></category>
		<category><![CDATA[NBIX]]></category>
		<category><![CDATA[Neurocrine Biosciences Inc]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>
		<category><![CDATA[OXBT]]></category>
		<category><![CDATA[Oxygen Biotherapeutics]]></category>
		<category><![CDATA[PBIO]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>
		<category><![CDATA[Pressure BioSciences Inc.]]></category>
		<category><![CDATA[SPEX]]></category>
		<category><![CDATA[Spherix Inc]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64740</guid>
		<description><![CDATA[Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology  industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference held at the Westin St. Francis Hotel. The event is attended by the “Who’s Who” of the healthcare industry, with currently over 350 companies registered to attend. Two smaller conferences will also take place next week concurrent with the massive J.P. Morgan conference, the 4th annual OneMed Forum 2011 held at the Sir Francis Drake Hotel and the Biotech Showcase 2011 held at the Parc 55 Wyndham Hotel feature smaller companies from the biotech and medical device industries. These conferences are an outstanding opportunity for biotech investors to meet ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TSPT) Transcept Pharmaceuticals &#8211; Don&#8217;t Lose Sleep Over Intermezzo</title>
		<link>http://www.stockbloghub.com/2010/03/29/tspt-transcept-pharmaceuticals-dont-lose-sleep-over-intermezzo/31914</link>
		<comments>http://www.stockbloghub.com/2010/03/29/tspt-transcept-pharmaceuticals-dont-lose-sleep-over-intermezzo/31914#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:06:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Somaxon Pharmaceuticals Inc]]></category>
		<category><![CDATA[SOMX]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31914</guid>
		<description><![CDATA[On January 20, 2010, Transcept Pharmaceuticals (TSPT) management met with the U.S. FDA to discuss the complete response letter issued October 28, 2009 on Intermezzo. The letter brought up issues on potential inadvertent re-dosing in a single night and inadvertent dosing with less than four hours of bedtime remaining.  The FDA also requested additional data demonstrating that Intermezzo, when taken as directed in the middle of the night, would not present an unacceptable risk of next day driving ability.  Prior to attending the meeting, management submitted a revised proposal for the resubmission of the Intermezzo new drug application (NDA) to the FDA for evaluation and comment.  In this briefing document, Transcept proposed a new Intermezzo bedside unit-dose package and patient instructions designed to reduce the possibility of patient dosing errors. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/tspt-transcept-pharmaceuticals-dont-lose-sleep-over-intermezzo/31914/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TSPT) Transcept Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2010/03/29/tspt-transcept-pharmaceuticals-bull-of-the-day/31967</link>
		<comments>http://www.stockbloghub.com/2010/03/29/tspt-transcept-pharmaceuticals-bull-of-the-day/31967#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:01:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31967</guid>
		<description><![CDATA[We are maintaining our positive bias on Transcept Pharmaceuticals (TSPT). We believe the stock is significantly undervalued at this level, and that the market is overly pessimistic on the ability of management to address the issues raised in the FDA&#8217;s complete response letter from last October. From what we have seen, management has an excellent plan to answer the questions brought up by the agency and we think everything could be ready to re-file by October 2010. That puts an action date in April 2011. With nearly $90 million in cash still on the books at year-end 2009 and a market value of only $105 million, Transcept offers enormous upside once Intermezzo is finally approved by the FDA. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/tspt-transcept-pharmaceuticals-bull-of-the-day/31967/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TSPT) Transcept Met With U.S. FDA Intermezzo</title>
		<link>http://www.stockbloghub.com/2010/01/23/tspt-transcept-met-with-u-s-fda-intermezzo/25775</link>
		<comments>http://www.stockbloghub.com/2010/01/23/tspt-transcept-met-with-u-s-fda-intermezzo/25775#comments</comments>
		<pubDate>Sat, 23 Jan 2010 20:55:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25775</guid>
		<description><![CDATA[On January 20, 2010, Transcept (TSPT) management met with the U.S. FDA to discuss the complete response letter issued last October on Intermezzo. The letter brought up issues on potential inadvertent re-dosing in a single night and inadvertent dosing with less than four hours of bedtime remaining. The FDA also requested additional data demonstrating that Intermezzo, when taken as directed in the middle of the night, would not present an unacceptable risk of next-day driving ability (for additional details on the letter, see our November 17, 2009 report). We do not expect management to comment publically on the meeting until the final minutes have been issued. This is usually a 30 to 45 day process, putting a potential release from the company on the future plans for the drug sometime ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/tspt-transcept-met-with-u-s-fda-intermezzo/25775/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TSPT) Transcept Gets Letter from FDA</title>
		<link>http://www.stockbloghub.com/2009/11/01/tspt-transcept-gets-letter-from-fda/19207</link>
		<comments>http://www.stockbloghub.com/2009/11/01/tspt-transcept-gets-letter-from-fda/19207#comments</comments>
		<pubDate>Sun, 01 Nov 2009 21:47:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19207</guid>
		<description><![CDATA[FDA Issues Complete Response Letter on Intermezzo On October 28, 2009, the U.S. FDA issued a complete response letter [CRL] on Transcept&#8217;s (TSPT) new drug application (NDA) for Intermezzo. The news has sent the shares down roughly 45%. TSPT is down now over 60% from the high following the stock’s 14% decline yesterday before the news was public (an obvious leak at the FDA). The Good The FDA stated that it believes Transcept has submitted substantial evidence of effectiveness for the use of Intermezzo in the as-needed treatment of insomnia characterized by difficulty returning to sleep after awakening in the middle of the night (MOTN).  The FDA also recognized that the Intermezzo data did not indicate significant next-day residual effects. The Bad The FDA requested additional data demonstrating that Intermezzo, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/tspt-transcept-gets-letter-from-fda/19207/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

